Compare with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs TORRENT PHARMA - Comparison Results

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES TORRENT PHARMA ALKEM LABORATORIES/
TORRENT PHARMA
 
P/E (TTM) x - 54.3 - View Chart
P/BV x 7.0 6.5 108.3% View Chart
Dividend Yield % 0.6 0.8 78.1%  

Financials

 ALKEM LABORATORIES   TORRENT PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
TORRENT PHARMA
Mar-18
ALKEM LABORATORIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5891,550 102.5%   
Low Rs1,2321,144 107.7%   
Sales per share (Unadj.) Rs417.5354.7 117.7%  
Earnings per share (Unadj.) Rs56.340.1 140.5%  
Cash flow per share (Unadj.) Rs64.764.2 100.8%  
Dividends per share (Unadj.) Rs12.7014.00 90.7%  
Dividend yield (eoy) %0.91.0 86.6%  
Book value per share (Unadj.) Rs292.9273.1 107.2%  
Shares outstanding (eoy) m119.57169.22 70.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.43.8 89.0%   
Avg P/E ratio x25.133.6 74.6%  
P/CF ratio (eoy) x21.821.0 103.9%  
Price / Book Value ratio x4.84.9 97.7%  
Dividend payout %22.634.9 64.6%   
Avg Mkt Cap Rs m168,653227,897 74.0%   
No. of employees `000NA14.7 0.0%   
Total wages/salary Rs m9,17111,353 80.8%   
Avg. sales/employee Rs ThNM4,083.0-  
Avg. wages/employee Rs ThNM772.3-  
Avg. net profit/employee Rs ThNM461.3-  
INCOME DATA
Net Sales Rs m49,91560,021 83.2%  
Other income Rs m1,6452,988 55.0%   
Total revenues Rs m51,56163,009 81.8%   
Gross profit Rs m8,48213,493 62.9%  
Depreciation Rs m1,0064,086 24.6%   
Interest Rs m6713,085 21.7%   
Profit before tax Rs m8,4519,310 90.8%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6062,529 63.5%   
Profit after tax Rs m6,7316,781 99.3%  
Gross profit margin %17.022.5 75.6%  
Effective tax rate %19.027.2 70.0%   
Net profit margin %13.511.3 119.4%  
BALANCE SHEET DATA
Current assets Rs m27,06252,623 51.4%   
Current liabilities Rs m15,32452,022 29.5%   
Net working cap to sales %23.51.0 2,346.5%  
Current ratio x1.81.0 174.6%  
Inventory Days Days67120 55.6%  
Debtors Days Days4176 54.2%  
Net fixed assets Rs m12,61085,016 14.8%   
Share capital Rs m239846 28.3%   
"Free" reserves Rs m34,49045,376 76.0%   
Net worth Rs m35,02746,222 75.8%   
Long term debt Rs m1,21241,115 2.9%   
Total assets Rs m54,387142,432 38.2%  
Interest coverage x13.64.0 338.5%   
Debt to equity ratio x00.9 3.9%  
Sales to assets ratio x0.90.4 217.8%   
Return on assets %13.66.9 196.5%  
Return on equity %19.214.7 131.0%  
Return on capital %24.914.2 175.1%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56314,580 45.0%   
Fx outflow Rs m3,0123,600 83.7%   
Net fx Rs m3,55210,980 32.3%   
CASH FLOW
From Operations Rs m7,2598,942 81.2%  
From Investments Rs m1,864-47,070 -4.0%  
From Financial Activity Rs m-9,27334,174 -27.1%  
Net Cashflow Rs m-150-3,655 4.1%  

Share Holding

Indian Promoters % 66.9 71.5 93.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 7.0 471.5%  
FIIs % 0.0 12.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 8.8 -  
Shareholders   68,381 26,511 257.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   PFIZER  GSK PHARMA  STRIDES PHARMA SCIENCE  WYETH LTD  ABBOTT INDIA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Flat; L&T and Tech Mahindra Top Losers(12:30 pm)

Share markets in India are presently trading on a volatile note. Sectoral indices are trading mixed with stocks in the capital goods sector and realty sector.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Nov 13, 2019 01:27 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - GLENMARK PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS